分化型甲状腺癌初始治疗期间甲状腺激素水平波动与止血系统变化相关:一项前瞻性队列研究
该研究在荷兰前瞻性队列中连续纳入20例分化型甲状腺癌患者,比较甲状腺功能正常、严重甲状腺功能减退及甲状腺激素抑制治疗(THST)期间的止血指标。THST期间多数止血蛋白升高,C反应蛋白(CRP)、凝血酶生成和血块溶解时间增加,纤溶酶-抗纤溶酶复合物(PAP)降低,提示高凝和低纤溶状态,但体内止血激活未增加。
要点
- THST期间CRP从1.3(0.5-3.3)升至3.2(1.3-5.1)mg/L(p < 0.01),提示低度炎症。
- THST期间凝血酶生成从626.0(477.0-836.3)升至876.0(699.0-1052.0)nM × min(p = 0.02)。
- THST期间血块溶解时间从60.6(55.6-67.4)延长至76.0(69.7-95.0)分钟(p < 0.01)。
核心结论
- THST诱导的甲状腺功能亢进期间出现高凝和低纤溶状态,但体内止血激活未增加;CRP升高提示低度炎症,这些细微变化可能与DTC患者心血管疾病风险相关。
研究设计与样本
- 荷兰前瞻性队列的二次研究,连续纳入20例接受DTC治疗的患者(18例女性[90%];中位年龄48[四分位距35.8-56.5]岁),在甲状腺功能正常(n = 5)、严重甲状腺功能减退(n = 20)和THST(n = 20)期间采集样本。
主要发现
- 甲状腺功能减退期间多数测量参数无变化。
- THST期间几乎所有测量的止血蛋白水平高于甲状腺功能减退期间。
- THST期间CRP从1.3(0.5-3.3)升至3.2(1.3-5.1)mg/L(p < 0.01)。
- THST期间凝血酶生成从626.0(477.0-836.3)升至876.0(699.0-1052.0)nM × min(p = 0.02),血块溶解时间从60.6(55.6-67.4)延长至76.0(69.7-95.0)分钟(p < 0.01)。
- THST期间PAP从266.5(211.8-312.0)降至192.0(161.0-230.0)μg/L(p < 0.01),其他体内凝血激活标志物未受影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: During treatment for differentiated thyroid carcinoma (DTC), patients go from euthyroidism to severe hypothyroidism to subclinical hyperthyroidism induced by thyroid hormone suppression therapy (THST). Severe hypothyroidism may induce a tendency toward bleeding, whereas hyperthyroidism is thrombogenic. Therefore, treatment for DTC may increase the risk of bleeding during thyroid hormone withdrawal, and thrombosis during THST. This study aims to provide prospective analysis of changes in the hemostatic system from euthyroidism to hypothyroidism, and during THST, in patients treated for DTC. Methods: This is a secondary study in a larger Dutch prospective cohort. Consecutive samples were obtained from 20 patients (18 female [90%]; median age 48 [interquartile range 35.8-56.5] years) throughout their treatment for DTC during euthyroidism (n = 5), severe hypothyroidism (n = 20), and THST (n = 20). We measured selected hemostatic proteins and C-reactive protein (CRP), performed functional tests of hemostasis (a thrombin generation test and a plasma-based clot lysis test), and assessed markers of in vivo activation of hemostasis (thrombin-antithrombin complexes, plasmin-antiplasmin [PAP] complexes, and D-dimer levels). Results: During hypothyroidism, the majority of measured parameters did not change. During THST, plasma levels of nearly all measured hemostatic proteins were higher than during hypothyroidism. Additionally, CRP significantly increased from 1.3 (0.5-3.3) to 3.2 (1.3-5.1) mg/L during THST (p < 0.01). Ex vivo thrombin generation increased from 626.0 (477.0-836.3) to 876.0 (699.0-1052.0) nM × min (p = 0.02), and ex vivo clot lysis time increased from 60.6 (55.6-67.4) to 76.0 (69.7-95.0) minutes during THST (p < 0.01). PAP levels reduced from 266.5 (211.8-312.0) to 192.0 (161.0-230.0) μg/L during THST (p < 0.01); other markers of in vivo activation of coagulation remained unaffected. Conclusions: During THST-induced hyperthyroidism, a shift toward a more hypercoagulable and hypofibrinolytic state occurred. However, in vivo activation of hemostasis did not increase. The rise in CRP levels suggests the presence of a low-grade inflammation in patients during THST. Both a hypercoagulable and hypofibrinolytic state and a low-grade inflammation are associated with an increased risk of cardiovascular diseases (CVD). Therefore, the subtle changes found during THST could potentially play a role in the pathogenesis of CVD as observed in DTC patients. Clinical Trial Registration: This study is part of a larger clinical trial registered at the Netherlands Trial Register (NTR ID 7228).
引用
- Links MH, Lefrandt JD, Lisman T, et al. Fluctuations in Thyroid Hormone Levels During Initial Treatment for Differentiated Thyroid Carcinoma are Associated with Changes in Hemostasis: A Prospective Cohort Study. Thyroid. 2022. PMID: 36322715. doi:10.1089/thy.2022.0299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。